Magnolia Neurosciences

Developer of therapies for treating neurodegenerative diseases and neuronal injuries

placeNew York City, New York, United States calendar_todayFounded 2018 groups1 employees language magnolianeurosciences.com

Registered entities

Investor mix

12 investors on record; lead investors include AbbVie, Acks, Arch Venture Partners, Lilly.

Investor typeCountShare
Venture capital650%
Accelerator & incubator18%
Other / undisclosed542%
Coming soon